ENANTA PHARMACEUTICALS INC Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enanta Pharmaceuticals Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Enanta Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $5.42M, a 22.6% decline year-over-year.
  • Enanta Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $25.8M, a 8.97% decline year-over-year.
  • Enanta Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2023 was $28.2M, a 4.62% increase from 2022.
  • Enanta Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2022 was $27M, a 28.5% increase from 2021.
  • Enanta Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2021 was $21M, a 7.23% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $28.2M +$1.25M +4.62% Oct 1, 2022 Sep 30, 2023 10-K 2023-11-22
2022 $27M +$5.98M +28.5% Oct 1, 2021 Sep 30, 2022 10-K 2023-11-22
2021 $21M +$1.42M +7.23% Oct 1, 2020 Sep 30, 2021 10-K 2023-11-22
2020 $19.6M +$349K +1.82% Oct 1, 2019 Sep 30, 2020 10-K 2022-11-23
2019 $19.2M +$3.38M +21.3% Oct 1, 2018 Sep 30, 2019 10-K 2021-11-24
2018 $15.8M +$2.77M +21.2% Oct 1, 2017 Sep 30, 2018 10-K 2020-11-25
2017 $13.1M +$3.72M +39.7% Oct 1, 2016 Sep 30, 2017 10-K 2019-11-27
2016 $9.35M +$3.52M +60.2% Oct 1, 2015 Sep 30, 2016 10-K 2018-11-29
2015 $5.84M +$3.16M +118% Oct 1, 2014 Sep 30, 2015 10-K 2017-12-11
2014 $2.68M Oct 1, 2013 Sep 30, 2014 10-K 2016-12-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.